Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 16/20 | 0.69 |
| ▸ | RARB | P10826 | 15/20 | 0.69 |
| ▸ | RARG | P13631 | 15/20 | 0.69 |
| ▸ | RARA | P10276 | 12/20 | 0.69 |
| ▸ | RXRB | P28702 | 7/20 | 0.69 |
| ▸ | RXRG | P48443 | 7/20 | 0.69 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.57 |
| ▸ | RECQL | P46063 | 2/20 | 0.57 |
| ▸ | BLM | P54132 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.57 |
| ▸ | ESR1 | P03372 | 1/20 | 0.57 |
| ▸ | PGR | P06401 | 1/20 | 0.57 |
| ▸ | HTR1A | P08908 | 1/20 | 0.57 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.57 |
| ▸ | DRD1 | P21728 | 1/20 | 0.57 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6260299 | 0.98 | RXRA (0.72) | RXRARARBRARGRARARXRB | |
| SCHEMBL6260306 | 0.98 | RXRA (0.72) | RXRARARBRARGRARARXRB | |
| SCHEMBL6429289 | 0.83 | RXRA (0.53) | RXRARARBRARGRARARXRB | |
| SCHEMBL27582113 | 0.83 | RXRA (0.53) | RXRARARBRARGRARARXRB | |
| SCHEMBL6258870 | 0.83 | RARB (0.70) | RXRARARBRARGRARARXRB | |
| SCHEMBL6258868 | 0.83 | RARB (0.70) | RXRARARBRARGRARARXRB | |
| SCHEMBL6429291 | 0.82 | RXRA (0.54) | RXRARARBRARGRARARXRB | |
| SCHEMBL3301839 | 0.82 | RARB (1.00) | RXRARARBRARGRARARXRB | |
| SCHEMBL5084708 | 0.82 | RARB (1.00) | RXRARARBRARGRARARXRB | |
| SCHEMBL3301842 | 0.82 | RARB (1.00) | RXRARARBRARGRARARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050004165-A1 | Composition and method for modulating BAR/FXR receptor activity | FORMAN BARRY M (US) | 2005-01-06 | — | — | US | disclosed |
| US-20030144360-A1 | Composition and method for modulating BAR/FXR receptor activity | ALLERGAN SALES, INC. | 2003-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004165-A1 | Composition and method for modulating BAR/FXR receptor activity | NR1H4, FXR1, GPBAR1 | RXRA 35/4885RARB 181/4885RARG 150/4885 |
| US-20030144360-A1 | Composition and method for modulating BAR/FXR receptor activity | NR1H4, FXR1, GPBAR1 | RXRA 35/4885RARB 181/4885RARG 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.